Filtered By:
Condition: Bleeding
Drug: Proton Pump Inhibitors PPIs

This page shows you your search results in order of date.

Order by Relevance | Date

Total 33 results found since Jan 2013.

< em > ABCG2 < /em > Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
CONCLUSION: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.PMID:37641689 | PMC:PMC10460569 | DOI:10.2147/DDDT.S417096
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Hamin Kim Tae-Jin Song Jeong Yee Dong-Hyeok Kim Junbeom Park Hye Sun Gwak Source Type: research

A nomogram for predicting major gastrointestinal bleeding in patients treated with rivaroxaban
CONCLUSION: The nomogram demonstrated good discrimination, calibration, and clinical applicability. Therefore, it could accurately predict the risk of MGIB in patients treated with rivaroxaban.PMID:37317530 | DOI:10.1080/00365521.2023.2220460
Source: Scandinavian Journal of Gastroenterology - June 15, 2023 Category: Gastroenterology Authors: Haiyan Cao Hongyan Xu Min Zhu Xinglin Chu Zhihuan Zhang Yongqi Dong Source Type: research

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding.
CONCLUSION: When NSAIDs or SSRIs are required for NOAC users with AF, physicians need to monitor bleeding events and consider the use of PPIs, especially for combined use of both drugs or when initiating NOACs treatment. PMID: 32882758 [PubMed - in process]
Source: Yonsei Medical Journal - August 31, 2020 Category: Universities & Medical Training Authors: Lee MT, Park KY, Kim MS, You SH, Kang YJ, Jung SY Tags: Yonsei Med J Source Type: research

Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?
Abstract Proton pump inhibitors (PPIs) are among the most widely prescribed agents, either for treatment or prophylaxis of gastrointestinal (GI) disease, that are often administered for prolonged or chronic use. Patients with cardiovascular (CV) disease frequently receive PPIs for prophylaxis against GI bleeding due to common use of antithrombotic drugs. Over the last several years there is a growing number of reports associating chronic PPI use with a variety of serious CV and non-CV adverse effects. In this context, PPI use has been independently associated with an increased risk of CV morbidity (myocardial infa...
Source: European Journal of Internal Medicine - November 29, 2019 Category: Internal Medicine Authors: Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS Tags: Eur J Intern Med Source Type: research

Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry.
CONCLUSIONS: These results indicate that the use of PPIs in patients with maintenance hemodialysis might increase mortality and cardiovascular events without decreasing the risk of bleeding. Therefore, it should always be analyzed if a patient truly needs PPIs. PMID: 31735546 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - November 13, 2019 Category: Internal Medicine Authors: Kosedo I, Tokushige A, Takumi T, Yoshikawa A, Teraguchi K, Takenouchi K, Shiraishi K, Ikeda D, Imamura M, Sonoda T, Kanda D, Ikeda Y, Ido A, Ohishi M Tags: Eur J Intern Med Source Type: research

Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels
This article reviews up to date data about the risk of gastric bleeding on dabigatran, the impact of PPI on the reduction of gastric bleeding, and the interaction between PPI and dabigatran leading to decreased dabigatran plasma levels. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Thrombosis and Hemostasis - September 18, 2019 Category: Hematology Authors: Bolek, Tom áš Samo š, Matej Škorňová, Ingrid Galajda, Peter Sta ško, Ján Kubisz, Peter Mok áň, Marián Tags: Review Article Source Type: research

Anticoagulation in Atherosclerotic Disease.
Abstract The prevention of atherothrombotic events is an essential therapeutic goal in the treatment of patients with arteriosclerotic diseases. After plaque rupture, a rapidly growing thrombus can lead to acute vascular occlusion and thus heart attack, stroke or limb ischaemia. The acute therapy combines anticoagulation and platelet inhibition. However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel. Despite the use of antiplatelet therapies, including aspirin and P2Y12-receptor antagonists, some patients with artery ...
Source: Hamostaseologie - October 17, 2018 Category: Hematology Authors: Al Said S, Bode C, Duerschmied D Tags: Hamostaseologie Source Type: research

Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Publication date: 9–15 June 2018 Source:The Lancet, Volume 391, Issue 10137 Author(s): P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, ...
Source: The Lancet - June 8, 2018 Category: General Medicine Source Type: research

New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study
ConclusionsGastrointestinal bleeding increased the risk of subsequent mortality during follow‐up of anticoagulated patients, highlighting the importance of prevention. The study developed a new scoring model for acute GI bleeding risk based on five factors (no‐proton pump inhibitor use, chronic kidney disease, chronic obstructive pulmonary disease, history of peptic ulcer disease, and liver cirrhosis), which was superior to the HAS‐BLED score.
Source: Journal of Gastroenterology and Hepatology - December 28, 2017 Category: Gastroenterology Authors: Akira Shimomura, Naoyoshi Nagata, Takuro Shimbo, Toshiyuki Sakurai, Shiori Moriyasu, Hidetaka Okubo, Kazuhiro Watanabe, Chizu Yokoi, Junichi Akiyama, Naomi Uemura Tags: Gastroenterology Source Type: research

Heartburn drugs linked to premature death
Conclusion This larger set of observational data finds that PPI drugs are associated with an increase in the risk of early death compared with either H2 blockers or no acid suppression drugs. This was the case for participants both with and without gastrointestinal problems. It also appears as though the longer the PPIs drugs are taken, the greater the risk of death. Considering that these drugs are widely used in the UK, these findings may cause concern. But the research has a number of important limitations: The study was conducted in a population of mostly white, older US male veterans, which might limit the ability...
Source: NHS News Feed - July 4, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
Publication date: Available online 13 June 2017 Source:The Lancet Author(s): Linxin Li, Olivia C Geraghty, Ziyah Mehta, Peter M Rothwell Background Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years. Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability. Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70–90%, uptake is low and guidelines are conflicti...
Source: The Lancet - June 15, 2017 Category: General Medicine Source Type: research

Risk of aspirin-related bleeding is higher in the over-75s
Conclusion This valuable cohort study helps to quantify the extent of bleeding risk in people taking aspirin for secondary prevention of cardiovascular disease. Aspirin is well known to carry bleeding risk – particularly in older adults – but this study suggests the risk may be higher than previously thought. The researchers say that for adults under the age of 75, the annual bleeding risk at around 1% is similar to that suggested by previous trials, as is the ratio of bleeds to the number of cardiovascular events. However, this risk increases for older adults, especially for major bleeds of the stomach and upper diges...
Source: NHS News Feed - June 14, 2017 Category: Consumer Health News Tags: Medication Older people Source Type: news